Table 3.
Factors that influence HIV/AIDS clinical trial participation, stratified by region and sex
| Characteristics | Total, N = 2070 (%)a |
Northeast (%) | Midwest (%) | South (%) | West (%) | Pb | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Male, n = 435 |
Female, n = 232 |
Male, n = 364 |
Female, n = 124 |
Male, n = 359 | Female, n = 137 |
Male, n = 355 |
Female, n = 64 |
|||
| Facilitators to participation | ||||||||||
| More of my sex represented | 517 (25) | 121 (28) | 67 (29) | 79 (22) | 28 (23) | 82 (23) | 47 (34) | 60 (17) | 33 (52) | <0.001 |
| More of my race represented | 539 (26) | 123 (28) | 69 (30) | 84 (23) | 25 (20) | 98 (27) | 47 (34) | 69 (19) | 24 (38) | 0.001 |
| Barriers to participation | ||||||||||
| Worry about a placebo | 343 (17) | 62 (14) | 25 (11) | 81 (22) | 12 (10) | 55 (15) | 14 (10) | 90 (25) | 4 (6) | <0.001 |
Only responses with statistically significant P values are included in table. AIDS, acquired immunodeficiency syndrome; HIV, human immunodeficiency virus.
a
Respondents who reported transgender (n = 13) or did not report sex (n = 44) were not included in analysis.
b
P values from χ2 test of independence.